Experts Discuss ADCs for HER2-Negative/Ultralow/Low MBC

In this podcast episode, Aditya Bardia, MD, MPH, FASCO, and Ruta Rao, MD, discuss ADCs for HER2-negative/ultralow/low metastatic breast cancer, including:

• Classifying HER2 expression in MBC today (HER2 negative/ultralow/low/positive) and why this is important
• ADCs for HER2-negative/ultralow/low MBC
• Patient communication: best practices in discussing treatment goals and potential AEs

Presenters: 

Aditya Bardia, MD, MPH, FASCO
Professor of Medicine
Geffen School of Medicine
University of California
Los Angeles, California

Ruta Rao, MD​
Medical Director, Rush University Cancer Center
Professor of Medicine
Rush University Medical Center
Chicago, Illinois ​

Content based on an online CME program supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

Link to full program: 
https://bit.ly/47JLtBt

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.